QOL OUTCOMES DURING LONG-TERM TREATMENT WITH DARIFENACIN FOR OVERACTIVE BLADDER (OAB): A 2-YEAR, OPEN-LABEL EXTENSION STUDY

被引：0
|
作者：
Young, Jay [1 ]
Lheritier, Karine [2 ]
Steel, Michael [3 ]
Dwyer, Peter [4 ]
机构：
[1] Orange Cty Urol Associates, Med Res Ctr, Laguna Woods, CA USA
[2] Novartis Pharma AG, Biostat, Basel, Switzerland
[3] Novartis Pharma AG, Clin Dev & Med Affairs, Basel, Switzerland
[4] Mercy Hosp Women, Urogynaecol, Melbourne, Vic, Australia
来源：
QUALITY OF LIFE RESEARCH | 2005年 / 14卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
P-36/1678
引用
收藏
页码：2036 / 2036
页数：1
相关论文
共 50 条
  • [1] Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study
    Haab, Francois
    Corcos, Jacques
    Siami, Paul
    Glavind, Karin
    Dwyer, Peter
    Steel, Michael
    Kawakami, Fernando
    Lheritier, Karine
    Steers, William D.
    BJU INTERNATIONAL, 2006, 98 (05) : 1025 - 1032
  • [2] Long-term darifenacin treatment for overactive bladder: Quality of life outcomes from a 2-year, open-label extension study
    Young, J
    Lheritier, K
    Steel, M
    Dwyer, P
    VALUE IN HEALTH, 2005, 8 (06) : A85 - A86
  • [3] Long-term persistence and compliance with darifenacin treatment for overactive bladder: results of a 2-year open-label extension study.
    Hill, S
    Lheritier, K
    Kawakami, F
    PHARMACOTHERAPY, 2005, 25 (10): : 1493 - 1493
  • [4] Long-term treatment of overactive bladder with darifenacin in older patients: Analysis of responder rates in a 2-year, open-label extension study
    不详
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (02) : 117 - 117
  • [5] Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study
    Hill, Simon
    Elhilali, Mostafa
    Millard, Richard J.
    Dwyer, Peter L.
    Lheritier, Karine
    Kawakami, Fernando T.
    Steel, Michael
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (11) : 2697 - 2704
  • [6] Efficacy, tolerability and safety of long-term darifenacin treatment in older patients with overactive bladder: Analysis of results from a 2-year, open-label extension study
    Dwyer, P.
    Lheritier, K.
    Steel, M.
    NEUROUROLOGY AND URODYNAMICS, 2006, 25 (06) : 657 - 658
  • [7] Long-term treatment with zonisamide: Results of a 2 year open-label extension study
    Wroe, S.
    Duncan, R.
    EPILEPSIA, 2006, 47 : 138 - 138
  • [8] Cisapride in the long-term treatment of chronic gastroparesis: A 2-year open-label study
    Kendall, BJ
    Kendall, ET
    Soykan, I
    McCallum, RW
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 1997, 25 (04) : 182 - 189
  • [9] Long-term use of solifenacin in pediatric patients with overactive bladder: Extension of a prospective open-label study
    Nadeau, Genevieve
    Schroeder, Annette
    Moore, Katherine
    Genois, Lucie
    Lamontagne, Pascale
    Hamel, Micheline
    Pellerin, Eve
    Bolduc, Stephane
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2014, 8 (3-4): : 118 - 123
  • [10] EFFICACY AND SAFETY OF LONG-TERM TREATMENT WITH LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: RESULTS OF A 2-YEAR, OPEN-LABEL EXTENSION STUDY
    Correll, C.
    Goldman, R.
    Tocco, M.
    Pikalov, A.
    Deng, L.
    Loebel, A.
    Coghill, D.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2019, 53 : 105 - 105
12345